Mark Gardner

2.2k total citations
39 papers, 1.4k citations indexed

About

Mark Gardner is a scholar working on Oncology, Genetics and Pharmacology. According to data from OpenAlex, Mark Gardner has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Genetics and 8 papers in Pharmacology. Recurrent topics in Mark Gardner's work include Estrogen and related hormone effects (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Mark Gardner is often cited by papers focused on Estrogen and related hormone effects (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Mark Gardner collaborates with scholars based in United States and France. Mark Gardner's co-authors include Jerome J. Schentag, William J. Jusko, Donald M. Hilligoss, Mark D. Rapport, George J. DuPaul, Colin B. Denney, Jeffrey R. Koup, John W. Vance, Antoinette Mangione and Robert A. Blum and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

Mark Gardner

37 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Gardner United States 17 275 257 236 234 217 39 1.4k
Robert A. Blum United States 24 180 0.7× 252 1.0× 396 1.7× 470 2.0× 284 1.3× 83 2.4k
Daniel M. Canafax United States 26 187 0.7× 80 0.3× 151 0.6× 302 1.3× 308 1.4× 86 2.5k
John H. Cavanaugh United States 23 256 0.9× 235 0.9× 245 1.0× 222 0.9× 351 1.6× 59 1.7k
Marco Villa Italy 25 295 1.1× 43 0.2× 193 0.8× 212 0.9× 102 0.5× 56 2.6k
Oscar Della Pasqua United Kingdom 25 264 1.0× 356 1.4× 182 0.8× 597 2.6× 602 2.8× 159 2.7k
Mario Ángel-González United States 18 188 0.7× 62 0.2× 40 0.2× 264 1.1× 164 0.8× 78 1.1k
David P. Figgitt New Zealand 29 149 0.5× 75 0.3× 297 1.3× 355 1.5× 117 0.5× 59 2.6k
Andrés Navarro‐Ruiz Spain 18 189 0.7× 36 0.1× 156 0.7× 267 1.1× 162 0.7× 75 1.3k
Prem Venkatesan India 20 66 0.2× 111 0.4× 508 2.2× 142 0.6× 64 0.3× 48 1.0k
Tomoko Inoue Japan 21 55 0.2× 168 0.7× 88 0.4× 74 0.3× 118 0.5× 176 1.7k

Countries citing papers authored by Mark Gardner

Since Specialization
Citations

This map shows the geographic impact of Mark Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Gardner more than expected).

Fields of papers citing papers by Mark Gardner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Gardner. The network helps show where Mark Gardner may publish in the future.

Co-authorship network of co-authors of Mark Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Gardner. A scholar is included among the top collaborators of Mark Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Gardner. Mark Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Papanicolau‐Sengos, Antonios, Sarabjot Pabla, Grace K. Dy, et al.. (2018). Correlation of lung cancer mutational profile with immune profile.. Journal of Clinical Oncology. 36(5_suppl). 146–146. 1 indexed citations
2.
Willis, William L., Linan Wang, Takuma Tsuzuki Wada, et al.. (2018). The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and forms high-molecular weight complexes with autoantigens. Journal of Biological Chemistry. 293(22). 8394–8409. 14 indexed citations
3.
Conroy, Jeffrey M., Sarabjot Pabla, Sean T. Glenn, et al.. (2017). Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. Journal of Molecular Diagnostics. 20(1). 95–109. 56 indexed citations
4.
Gandhi, Shipra, Sarabjot Pabla, Mary Nesline, et al.. (2017). Algorithmic prediction of response to checkpoint inhibitors: Hyperprogressors versus responders.. Journal of Clinical Oncology. 35(15_suppl). 11565–11565. 3 indexed citations
5.
Young, Nicholas A., Mark Gardner, William L. Willis, et al.. (2014). Oral Administration of Nano-Emulsion Curcumin in Mice Suppresses Inflammatory-Induced NFκB Signaling and Macrophage Migration. PLoS ONE. 9(11). e111559–e111559. 49 indexed citations
6.
Prakash, Chandra, Kim A. Johnson, & Mark Gardner. (2008). Disposition of Lasofoxifene, a Next-Generation Selective Estrogen Receptor Modulator, in Healthy Male Subjects. Drug Metabolism and Disposition. 36(7). 1218–1226. 13 indexed citations
7.
Gardner, Mark, et al.. (2006). Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women. The Journal of Clinical Pharmacology. 46(1). 52–58. 21 indexed citations
8.
Bramson, Candace, et al.. (2006). A Single‐Dose Pharmacokinetic Study of Lasofoxifene in Healthy Volunteers and Subjects With Mild and Moderate Hepatic Impairment. The Journal of Clinical Pharmacology. 46(1). 29–36. 12 indexed citations
9.
Ouellet, Danièle, et al.. (2006). Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. British Journal of Clinical Pharmacology. 63(1). 59–66. 17 indexed citations
10.
Fountaine, Robert J., et al.. (2006). Clinical Pharmacology of Lasofoxifene in Japanese and White Postmenopausal Women. The Journal of Clinical Pharmacology. 46(6). 693–699. 6 indexed citations
11.
Bramson, Candace, et al.. (2005). Effect of Lasofoxifene on the Pharmacokinetics of Digoxin in Healthy Postmenopausal Women. The Journal of Clinical Pharmacology. 45(12). 1407–1412. 13 indexed citations
12.
Fisher, Jeannine M., Ann E. Taylor, Sheela Kolluri, et al.. (2005). Effects of Steady-State Lasofoxifene on Cyp2D6- and Cyp2E1-Mediated Metabolism. Annals of Pharmacotherapy. 40(1). 32–37. 10 indexed citations
13.
Hoover, Dennis J., Bruce A. Lefker, Robert L. Rosati, et al.. (1995). Discovery of Inhibitors of Human Renin with High Oral Bioavailability. Advances in experimental medicine and biology. 362. 167–180. 11 indexed citations
14.
Rapport, Mark D., Colin B. Denney, George J. DuPaul, & Mark Gardner. (1994). Attention Deficit Disorder and Methylphenidate: Normalization Rates, Clinical Effectiveness, and Response Prediction in 76 Children. Journal of the American Academy of Child & Adolescent Psychiatry. 33(6). 882–893. 167 indexed citations
15.
Blum, Robert A., et al.. (1991). Effect of fluconazole on the disposition of phenytoin. Clinical Pharmacology & Therapeutics. 49(4). 420–425. 91 indexed citations
16.
Blum, Robert A., et al.. (1991). Increased Gastric pH and the Bioavailability of Fluconazole and Ketoconazole. Annals of Internal Medicine. 114(9). 755–757. 134 indexed citations
17.
Apseloff, Glen, et al.. (1991). Induction of Fluconazole Metabolism by Rifampin: In Vivo Study in Humans. The Journal of Clinical Pharmacology. 31(4). 358–361. 51 indexed citations
18.
Canafax, Daniel M., Nina M. Graves, Donald M. Hilligoss, et al.. (1991). INTERACTION BETWEEN CYCLOSPORINE AND FLUCONAZOLE IN RENAL ALLOGRAFT RECIPIENTS. Transplantation. 51(5). 1014–1017. 95 indexed citations
19.
Tornatore, Kathleen M., et al.. (1988). Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clinical Pharmacology & Therapeutics. 43(1). 23–31. 26 indexed citations
20.
Gardner, Mark, et al.. (1984). Theophylline disposition in residents living near a chemical waste site. Biopharmaceutics & Drug Disposition. 5(4). 345–355. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert A. Blum Breakdown of academic impact, for papers by Daniel M. Canafax Breakdown of academic impact, for papers by John H. Cavanaugh Breakdown of academic impact, for papers by Marco Villa Breakdown of academic impact, for papers by Oscar Della Pasqua Breakdown of academic impact, for papers by Mario Ángel-González Breakdown of academic impact, for papers by David P. Figgitt Breakdown of academic impact, for papers by Andrés Navarro‐Ruiz Breakdown of academic impact, for papers by Prem Venkatesan Breakdown of academic impact, for papers by Tomoko Inoue
Rankless by CCL
2026